Clin2
NCT07604350Possibly a fitNot yet recruiting

Edaravone Dexborneol to Prevent Seizures After Stroke

Post-stroke EpilepsyPost-stroke Seizure

Part of Brain & nervous system clinical trials.

This study tests whether a combination medicine (edaravone dexborneol) can prevent seizures in people who have just had an ischemic stroke (a stroke caused by a blood clot). You would receive this medicine within 48 hours of your stroke if you're at high risk for developing seizures.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
160 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You are 18–80 years old and had an ischemic stroke (confirmed by brain scan) within the past 48 hours
  • You are at high risk for post-stroke seizures based on a scoring system that looks at stroke severity, location, and brain wave patterns
  • You have never had epilepsy or seizures before this stroke, and no other brain conditions that cause seizures
  • You are awake or have regained consciousness, and can swallow medicine and participate in follow-up visits
  • You do not have severe kidney or liver disease, severe heart failure, or a severe allergy to edaravone or borneol
  • You are not pregnant, not breastfeeding, and willing to use contraception if of childbearing age

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06674460Recruiting· Phase 3
Edaravone Dexborneol tablet for stroke recovery

This trial tests a new sublingual tablet (Edaravone Dexborneol) to help people recover after a small stroke caused by disease of the small blood vessels in the brain. It aims to see if the drug can improve thinking and daily function.

Beijing
NCT06645522Not yet recruiting· Phase 4
Study of edaravone dexborneol for acute stroke

This trial tests a medicine called edaravone dexborneol for people who have had an acute ischemic stroke (a stroke caused by a blood clot). The goal is to see if it is safe and helps improve recovery when given within 48 hours of the stroke starting.

Changchun, Jilin
NCT07091994Not yet recruiting· Phase 4
Edaravone Dexborneol for Stroke With Active Cancer

This trial tests whether a combination medicine (edaravone dexborneol) can help people who have both a recent ischemic stroke and an active cancer. The study aims to see if the medication improves recovery without interfering with cancer care.

Guangzhou, Baiyun
NCT07682922Not yet recruiting· Phase 4
Sublingual stroke medicine for transfer to a treatment center

This trial tests if a sublingual (under the tongue) medication called Edaravone Dexborneol can help stroke patients who are being transferred from one hospital to another for a specialized procedure to remove a clot.

Chongqing, Chongqing Municipality
NCT06315231Recruiting· Phase 2
Stroke Recovery Thinking Trial for Recent Stroke Patients

This study tests an under-the-tongue tablet (edaravone dexborneol) to help thinking and memory problems that can happen after an ischemic stroke. It may help people who recently had a stroke and now have trouble with attention, memory, or planning.

Fuyang, Anhui
NCT07260760Not yet recruiting
Testing a neuroprotective drug for recent stroke

This trial studies the safety and effectiveness of edaravone, a neuroprotective drug, in people who have had a mild to moderate stroke in the front part of the brain within the last 48 hours. It aims to see if this drug can help protect the brain from further damage.

Hear when a new Post Stroke Epilepsy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.